The US Food and Drug Administration (FDA) has approved a subcutaneous injectable methotrexate delivered in an auto-injector (Rasuvo, Medac Pharma) for rheumatoid arthritis (RA), polyarticular-course ...
FDA to Review MPI-2505 NDA for RA, Psoriasis Medac Pharma announced the launch of Rasuvo (methotrexate) injection for patients with rheumatoid arthritis, polyarticular course juvenile idiopathic ...
FDA to Review MPI-2505 NDA for RA, Psoriasis Medac Pharma announced that the FDA has approved Rasuvo (methotrexate) subcutaneous auto-injector for the management of rheumatoid arthritis, polyarticular ...
Methotrexate injection, a treatment for certain autoimmune diseases and cancers, can lead to various side effects. These range from common, mild reactions such as headache and nausea to serious, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results